Wall Street Zen Upgrades Context Therapeutics (NASDAQ:CNTX) to Hold

Context Therapeutics (NASDAQ:CNTX) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

A number of other brokerages also recently commented on CNTX. JonesTrading started coverage on Context Therapeutics in a research note on Monday, December 22nd. They issued a “buy” rating and a $7.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Context Therapeutics in a research report on Wednesday, January 21st. Finally, Lifesci Capital upgraded Context Therapeutics to a “strong-buy” rating in a research report on Monday, February 23rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $6.00.

Context Therapeutics Stock Down 3.6%

Shares of NASDAQ:CNTX opened at $2.88 on Friday. Context Therapeutics has a fifty-two week low of $0.49 and a fifty-two week high of $3.62. The firm has a 50-day simple moving average of $2.35 and a 200 day simple moving average of $1.57. The company has a market cap of $264.71 million, a PE ratio of -12.00 and a beta of 1.97.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Clear Harbor Asset Management LLC raised its holdings in shares of Context Therapeutics by 60.5% during the third quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock valued at $90,000 after buying an additional 35,000 shares during the last quarter. Vanguard Group Inc. grew its holdings in Context Therapeutics by 4.0% in the 3rd quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after buying an additional 134,449 shares in the last quarter. Citadel Advisors LLC acquired a new stake in Context Therapeutics in the 3rd quarter valued at approximately $100,000. Blue Owl Capital Holdings LP increased its position in Context Therapeutics by 0.3% in the 4th quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock valued at $10,926,000 after acquiring an additional 25,000 shares during the period. Finally, Renaissance Technologies LLC raised its stake in Context Therapeutics by 58.8% during the 4th quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock valued at $747,000 after acquiring an additional 188,202 shares in the last quarter. Institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.